NASDAQ$NRC
NRC Health · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
NRC Health's financial performance decreased compared to the same quarter last year.
NRC Health announced its Q3 2024 results, with revenue at approximately $35.8 million, a decrease from $37.9 million in the 2023 quarter. Earnings per diluted share were $0.24, also down from $0.32 in the previous year.
- Revenue for the quarter was approximately $35.8 million, down from $37.9 million in Q3 2023.
- Earnings per diluted share decreased to $0.24, compared to $0.32 in the same quarter last year.
- Net indebtedness stood at approximately $50.2 million as of September 30, 2024.
- The company returned approximately $11.5 million to stockholders through dividends and stock repurchases.
Headline financials
Revenue & EPS history
NRC · Revenue · Quarterly
$35.8M
Forward guidance
The press release contains forward-looking statements regarding future dividends, which are subject to risks and uncertainties as detailed in the company's filings with the Securities and Exchange Commission.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.3%
Avg return
30 days after
54%
28 / 52 earnings
Positive
+16.1%
Q3 2025
Best reaction
-19.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +7.9% | +16.0% | |
| Q4 2025 | -19.9% | -27.2% | -35.9% | |
| Q3 2025 | +16.1% | +17.0% | +51.2% | |
| Q2 2025 | +2.1% | +4.8% | +6.7% | |
| Q1 2025 | +7.0% | +7.6% | +20.2% | |
| Q4 2024 | -11.9% | -11.0% | -22.6% | |
| Q3 2024 | +2.6% | -2.1% | +4.5% | |
| Q2 2024 | -11.7% | -9.3% | -7.2% | |
| Q1 2024 | -15.3% | -11.6% | -23.7% | |
| Q4 2023 | +2.2% | +0.6% | +1.7% | |
| Q3 2023 | -1.9% | -0.3% | -1.1% | |
| Q2 2023 | +2.2% | -0.4% | -2.6% | |
| Q1 2023 | -8.3% | -5.2% | -1.2% | |
| Q4 2022 | +4.8% | +5.3% | -1.8% | |
| Q3 2022 | -13.5% | -8.3% | -3.5% | |
| Q2 2022 | -4.1% | -7.4% | -12.8% | |
| Q1 2022 | -5.3% | -3.6% | +5.0% | |
| Q4 2021 | -1.5% | -4.5% | -4.7% | |
| Q3 2021 | +6.7% | +6.7% | -8.1% | |
| Q2 2021 | -0.8% | -0.2% | +1.6% | |
| Q1 2021 | -10.2% | -5.1% | -7.0% | |
| Q4 2020 | -0.7% | -3.9% | +0.3% | |
| Q3 2020 | +1.8% | -0.1% | -7.8% | |
| Q2 2020 | -4.1% | -1.0% | -3.0% | |
| Q1 2020 | +4.6% | +10.3% | +12.7% | |
| Q4 2019 | +0.3% | +1.8% | -36.0% | |
| Q3 2019 | -0.4% | +0.2% | +7.5% | |
| Q2 2019 | +3.0% | +2.6% | +1.0% | |
| Q1 2019 | +7.1% | +13.1% | +26.5% | |
| Q4 2018 | +0.6% | +2.7% | +0.2% | |
| Q3 2018 | +3.5% | +2.4% | +4.8% | |
| Q2 2018 | -0.3% | -0.3% | +2.4% | |
| Q1 2018 | +7.3% | +5.5% | +5.4% | |
| Q4 2017 | -7.4% | -7.9% | -9.7% | |
| Q3 2017 | -10.1% | -11.5% | -7.7% | |
| Q2 2017 | +0.9% | +1.7% | +9.9% | |
| Q1 2017 | +0.8% | -3.4% | -3.0% | |
| Q4 2016 | -3.0% | -4.9% | +0.5% | |
| Q3 2016 | -4.6% | -1.0% | +5.2% | |
| Q2 2016 | +0.3% | +2.3% | +2.2% | |
| Q1 2016 | +2.0% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +1.5% | — | — | |
| Q2 2015 | -2.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +0.9% | — | — | |
| Q2 2014 | +3.8% | — | — | |
| Q1 2014 | +3.9% | — | — | |
| Q4 2013 | +5.1% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q2 2013 | -1.2% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q4 2009 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro